Open to all conference attendees.

Gene therapies are revolutionizing treatment for genetic diseases. While these often one-time treatments can cure or slow the progression of aggressive, debilitating, sometimes fatal conditions, they come with prices as high as $4.25 million for a single dose.

The traditional US health insurance model is not designed to accommodate significant upfront costs, leaving plan sponsors struggling to provide equitable, sustainable coverage. And because the gene therapy landscape is rapidly evolving, current financial strategies aren’t keeping up with the financial risk-management realities facing employers/purchasers.

This session will explore existing and emerging solutions, assessing how best to support employees and their families who are gene therapy candidates.